Anika Therapeutics Inc., based in Bedford, Mass., announced on May 12, 2025, the issuance of non-statutory stock options under its 2021 Inducement Plan. The company granted options covering 5,000 shares of common stock at an exercise price of $14.46 per share, equating to the closing price on the Nasdaq Global Select Market on May 1, 2025. These options were awarded to two newly hired non-executive employees as part of their employment compensation package. The options will vest in increments of one-third on the first three anniversaries of the grant date, contingent upon continuous service to Anika. The options are set to expire on the tenth anniversary of the grant date unless terminated earlier according to their terms. These grants were approved by Anika's compensation committee and are not subject to stockholder approval.